Trials / Completed
CompletedNCT01124851
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
A Multiple Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ABT-652 Administered Once Daily to Subjects With an Excessive Daytime Sleepiness Disorder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness. Subjects will be randomized to either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-652 | See arm description for details |
| DRUG | Placebo | See arm description for details |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-05-17
- Last updated
- 2011-07-04
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01124851. Inclusion in this directory is not an endorsement.